BioWorld

June 1, 2004

Avastin, Erbitux Pace Up In Colorectal Market Race

Avigen Stops Coagulin-B Phase I, Plans Drug's Future With Bayer

Expanded Access For Genasense Stopped; Partners Behind Drug

Holiday notice

BioWorld Today's offices are closed Monday, May 31, in observance of Memorial Day. No issue will published that day. Read More

Indevus' Sanctura Gets FDA Nod For Overactive Bladder

Breathing a sigh of satisfaction after years of hard work, officials at Indevus Pharmaceuticals Inc. reached a long-awaited milestone on Friday with the FDA approval of Sanctura. (BioWorld Today) Read More

More Of The Same: Alnylam Gets IPO Done, Below Range

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...